EirGenix Inc. (TPE:6589)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
45.60
-1.40 (-2.98%)
At close: Apr 24, 2026
Market Cap13.80B -41.5%
Revenue (ttm)1.01B -0.4%
Net Income-760.55M
EPS-2.51
Shares Out302.65M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,832,036
Average Volume926,797
Open47.25
Previous Close47.00
Day's Range45.15 - 47.30
52-Week Range45.15 - 84.30
Beta0.67
RSI21.43
Earnings DateMay 8, 2026

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 1,000
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6589
Full Company Profile

Financial Performance

In 2025, EirGenix's revenue was 1.01 billion, a decrease of -0.38% compared to the previous year's 1.01 billion. Losses were -760.55 million, 8.91% more than in 2024.

Financial Statements